Europe

Intellectual Property and Regulatory Law: Recent Developments

https://pharmaphorum.com/partner-content-market-access/intellectual-property-and-regulatory-law-recent-developments/

Sandoz weighs into European rituximab biosimilar market

https://pharmaphorum.com/news/sandoz-weighs-european-rituximab-biosimilar-market/

Putting patients as partners

https://pharmaphorum.com/views-and-analysis/putting-patients-partners/

Are European incentives speeding access in rare cancer treatments?

https://pharmaphorum.com/views-and-analysis/european-incentives-speeding-access-rare-cancer-treatments/

Janssen’s quarterly schizophrenia drug approved in EU

https://pharmaphorum.com/news/janssens-quarterly-schizophrenia-drug-approved-in-eu/

Brexit would be a blow for UK life sciences – regulators and pharma alike

https://pharmaphorum.com/articles/brexit-would-be-a-blow-for-uk-life-sciences-regulators-and-pharma-alike/

An empowered patient means an empowered Europe

https://pharmaphorum.com/views-and-analysis/an-empowered-patient-means-an-empowered-europe/

Obstacles to true patient centricity in Europe

https://pharmaphorum.com/views-and-analysis/obstacles-to-true-patient-centricity-in-europe/

AbbVie’s hep C combination approved in Europe

https://pharmaphorum.com/news/abbvies-hep-c-combination-approved-in-europe/

1 2

Close in 10 seconds

Pharmaphorum.com

Search